BACKGROUND: Although molecular testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) is highly sensitive, the cost can be prohibitive. Those high costs are amplified when the recommended screening approach is used, which requires separate testing of specimens from 3 anatomic sites (rectal, pharyngeal and urogenital). Although individual molecular testing is standard of care, pooled testing may offer a cost-saving alternative. METHODS: Using the Xpert® CT/NG assay (Cepheid, Sunnyvale, CA) we tested urine, rectal and pharyngeal swabs for CT and NG in a high-risk cohort of participants assigned male at birth who reported sex with other persons who were assigned male at birth. Remnant specimens (0.34 mL from each anatomic site) were combined to perform a single 'pooled' test. We calculated positive and negative percent agreement between the pooled testing results with standard of care Xpert CT/NG test results as the reference. RESULTS: We conducted 644 pooled tests. Of those, 598 (92.3%) gave CT and NG results. The CT-positive and -negative percent agreement were 90.1% (95% confidence interval [CI], 80.7-95.9%) and 99.2% (98.1-99.8%), respectively. The NG-positive and -negative percent agreement were 96.2% (95% CI, 86.8-99.5%) and 99.8% (95% CI, 99.0-100%), respectively. Pooled testing identified 4 CT and 1 NG infections that were negative at all anatomic sites by individual testing. CONCLUSIONS: Three-site pooled CT and NG testing performs similarly to single anatomic site testing among tests providing a valid result. Future cost analyses should evaluate the cost effectiveness of pooled 3-site testing to determine if such a strategy improves the feasibility and accessibility of molecular sexually transmitted infection testing.
BACKGROUND: Although molecular testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) is highly sensitive, the cost can be prohibitive. Those high costs are amplified when the recommended screening approach is used, which requires separate testing of specimens from 3 anatomic sites (rectal, pharyngeal and urogenital). Although individual molecular testing is standard of care, pooled testing may offer a cost-saving alternative. METHODS: Using the Xpert® CT/NG assay (Cepheid, Sunnyvale, CA) we tested urine, rectal and pharyngeal swabs for CT and NG in a high-risk cohort of participants assigned male at birth who reported sex with other persons who were assigned male at birth. Remnant specimens (0.34 mL from each anatomic site) were combined to perform a single 'pooled' test. We calculated positive and negative percent agreement between the pooled testing results with standard of care Xpert CT/NG test results as the reference. RESULTS: We conducted 644 pooled tests. Of those, 598 (92.3%) gave CT and NG results. The CT-positive and -negative percent agreement were 90.1% (95% confidence interval [CI], 80.7-95.9%) and 99.2% (98.1-99.8%), respectively. The NG-positive and -negative percent agreement were 96.2% (95% CI, 86.8-99.5%) and 99.8% (95% CI, 99.0-100%), respectively. Pooled testing identified 4 CT and 1 NG infections that were negative at all anatomic sites by individual testing. CONCLUSIONS: Three-site pooled CT and NG testing performs similarly to single anatomic site testing among tests providing a valid result. Future cost analyses should evaluate the cost effectiveness of pooled 3-site testing to determine if such a strategy improves the feasibility and accessibility of molecular sexually transmitted infection testing.
Authors: Duygu Durukan; Tim R H Read; Catriona S Bradshaw; Christopher K Fairley; Deborah A Williamson; Vesna De Petra; Kate Maddaford; Rebecca Wigan; Marcus Y Chen; Anne Tran; Eric P F Chow Journal: J Clin Microbiol Date: 2020-04-23 Impact factor: 5.948
Authors: Joshua D Trebach; C Patrick Chaulk; Kathleen R Page; Susan Tuddenham; Khalil G Ghanem Journal: Sex Transm Dis Date: 2015-05 Impact factor: 2.830
Authors: Remco P H Peters; Noëmi Nijsten; Johan Mutsaers; Casper L Jansen; Servaas A Morré; A Petra van Leeuwen Journal: Sex Transm Dis Date: 2011-09 Impact factor: 2.830
Authors: Claire S Danby; Lisa A Cosentino; Lorna K Rabe; Carol L Priest; Khrystine C Damare; Ingrid S Macio; Leslie A Meyn; Harold C Wiesenfeld; Sharon L Hillier Journal: Sex Transm Dis Date: 2016-02 Impact factor: 2.830
Authors: Steven G Badman; Sara F E Bell; Judith A Dean; Jime Lemoire; Luke Coffey; Joseph Debattista; Andrew M Redmond; Owain D Williams; Charles F Gilks; David M Whiley Journal: Sex Health Date: 2020-02 Impact factor: 2.706